Glycopeptide Antibiotics Market Report 2026

The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.78 billion in 2025 to $4.13 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to increase in hospital-acquired infections, widespread use of vancomycin as standard therapy, rising prevalence of gram-positive bacterial infections, limited availability of alternative antibiotics, expansion of inpatient healthcare infrastructure.

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.89 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growth in multidrug-resistant pathogens, increasing adoption of long-acting glycopeptides, rising demand for outpatient and home-based antibiotic therapy, continued r&d in next-generation glycopeptides, growing global healthcare expenditure. Major trends in the forecast period include rising dependence on glycopeptides for resistant infections, expansion of lipoglycopeptide antibiotics portfolio, increased hospital use of intravenous glycopeptides, growing focus on optimized dosing and therapeutic monitoring, wider adoption in severe gram-positive infections.

The rising prevalence of gram-positive infections is expected to drive the growth of the glycopeptide antibiotic market in the coming years. Gram-positive infections are caused by bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and others. Glycopeptide antibiotics are highly effective against many gram-positive bacteria due to their mechanism of action, which targets bacterial cell wall synthesis. For example, in June 2023, the UK Health Security Agency, a UK-based government body responsible for public health and infectious disease control, reported in its Group A Streptococcal Infections: Report on Seasonal Activity in England 2022-2023 that invasive Group A Streptococcus (iGAS) activity rose sharply, with 509 laboratory-confirmed iGAS cases by week 46 of 2023, including a weekly peak of 73 cases. This increase highlights the growing burden of infectious diseases and intensifies demand for effective antimicrobial therapies. Therefore, the rising prevalence of gram-positive infections is driving the glycopeptide antibiotic market.

Leading companies in the glycopeptide antibiotics market are focusing on developing innovative products, such as novel glycopeptide scaffolds, to gain a competitive edge. Novel glycopeptide scaffolds are structurally unique antibiotic backbones created through advanced biosynthetic techniques or natural-product mining. For example, in May 2025, a China-European research consortium introduced Saarvienin A, a newly discovered glycopeptide featuring a halogenated peptide core, an unusual ureido linkage, and five distinct sugar or aminosugar units. Unlike traditional glycopeptides, Saarvienin A does not bind the conventional cell-wall target, suggesting a potentially novel mechanism of action, and demonstrates potent in vitro activity against resistant Gram-positive pathogens, including MRSA and vancomycin-resistant Enterococcus. While this innovation represents a significant advance in combating antibiotic resistance, it also faces challenges such as clinical translation, safety optimization, and scaling up production.

In January 2023, Fairlong Capital LLC, a U.S.-based investment firm, acquired DoseMeRx for an undisclosed amount. Through this acquisition, Fairlong Capital aims to strengthen its precision dosing capabilities and enhance patient outcomes with advanced medication management solutions. This strategic move enables the company to leverage innovative technology for more effective healthcare delivery. DoseMeRx, a U.S.-based Bayesian dosing platform, optimizes dosing for glycopeptide antibiotics, such as vancomycin, by personalizing treatment according to patient-specific factors.

Major companies operating in the glycopeptide antibiotics market are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.

North America was the largest region in the glycopeptide antibiotics market in 2025. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glycopeptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have introduced cost pressures in the glycopeptide antibiotics market by increasing prices of imported active pharmaceutical ingredients, fermentation inputs, and sterile injectable manufacturing equipment. These impacts are most evident in parenteral formulations such as vancomycin, dalbavancin, and oritavancin, with Asia-Pacific and emerging markets being more affected due to dependence on cross-border raw material sourcing. Hospitals and specialty clinics face higher procurement costs, potentially slowing adoption. However, tariffs are also encouraging local api production, regional manufacturing investments, and supply chain diversification, creating long-term resilience opportunities.

The glycopeptide antibiotics market research report is one of a series of new reports that provides glycopeptide antibiotics market statistics, including glycopeptide antibiotics industry global market size, regional shares, competitors with a glycopeptide antibiotics market share, detailed glycopeptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the glycopeptide antibiotics industry. This glycopeptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glycopeptide antibiotics are a class of antibiotics composed of glycosylated cyclic or polycyclic non-ribosomal peptides, which work by inhibiting bacterial cell wall synthesis. They were originally discovered in plant and soil bacteria.

The main drugs in the glycopeptide antibiotic category include vancomycin, dalbavancin, oritavancin, and others. Vancomycin, a widely used glycopeptide antibiotic, targets microorganisms in the intestines and is commonly prescribed to treat colitis that can develop following antibiotic therapy. These antibiotics are administered via oral, parenteral, and other routes to treat conditions such as skin and soft tissue infections, meningitis, Clostridioides difficile infection, enterocolitis, and other indications. They are used across hospitals, specialty clinics, home care, and other healthcare settings.

The glycopeptide antibiotics market consists of sales of teicoplanin, telavancin and ramoplanin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.